Stock price movements
On February 15, Teva Pharmaceutical (TEVA) closed at $17.98, 4.05% higher than its previous closing price, 23.24% higher than its 52-week low of $14.59, and 30.74% lower than its 52-week high of $25.96. Its market cap was $20.00 billion, and its forward PE, price-to-sales, and price-to-book ratios were 6.37x, 1.01x, and 1.32x, respectively.
After its fourth-quarter earnings release on February 13, Teva Pharmaceutical stock fell 5.96% from $19.12 on February 12 to $17.98 on February 15. The company reported revenue of $4.56 billion in the fourth quarter—$30 million higher than analysts’ consensus estimate despite being a YoY (year-over-year) fall of 15.6%. Teva also reported adjusted EPS of $0.53 in the quarter, a YoY fall of 43.01% and $0.02 lower than the consensus estimate.
Based on its closing price on February 15, the company reported returns of -1.32% in the last week, -3.59% in the last month, -23.59% in the last quarter, -19.98% in the last half year, -6.98% in the last year, and 16.60% YTD (year-to-date).
On February 15, the broader healthcare sector represented by the Health Care Select Sector SPDR ETF (XLV) reported returns of 3.24% in the last week, 5.22% in the last month, 1.98% in the last quarter, 3.25% in the last half year, 10.71% in the last year, and 7.33% YTD.
Teva Pharmaceutical has outperformed XLV YTD in 2019.
Analysts’ recommendations and target prices
Analysts’ 12-month consensus recommendation for Teva Pharmaceutical is a “hold.”
Of the 23 analysts covering Teva, two have given it “strong buys,” five have given it “buys,” 14 have given it “holds,” and two have given it “sells.” Their 12-month target price on the stock is $21.23, 18.08% higher than its closing price on February 15. The highest target price estimate for the stock is $30, and the lowest is $12.1.